SCHEMBL16573976

SCHEMBL16573976

Cc1ccc(-c2ccc3ncsc3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.60
FFAR1 O14842 1/20 0.48
TGFBR1 P36897 9/20 0.47
BMPR1A P36894 1/20 0.47
SMAD2 Q15796 1/20 0.47
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HKDC1 Q2TB90 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
APP P05067 1/20 0.46
RIPK1 Q13546 1/20 0.46
PFKFB3 Q16875 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 1/20 0.44
VRK1 Q99986 1/20 0.44
IKBKB O14920 1/20 0.43
HPGD P15428 1/20 0.43
KLK7 P49862 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31214345 0.88 DYRK1A (0.72) DYRK1AFFAR1TGFBR1BMPR1ASMAD2
SCHEMBL27550527 0.87 DYRK1A (0.63) DYRK1AFFAR1TGFBR1BMPR1ASMAD2
SCHEMBL6650934 0.85 FFAR1 (0.48) DYRK1AFFAR1TGFBR1RIPK1ALDH1A1
SCHEMBL29870814 0.84 RAB9A (0.54) DYRK1ATGFBR1BMPR1ASMAD2KDM4E
SCHEMBL266440 0.84 RAB9A (0.54) DYRK1ATGFBR1BMPR1ASMAD2KDM4E
SCHEMBL6032917 0.83 DYRK1A (0.62) DYRK1AFFAR1TGFBR1BMPR1ASMAD2
SCHEMBL24155396 0.81 DYRK1A (0.60) DYRK1AFFAR1TGFBR1BMPR1ASMAD2
SCHEMBL6658073 0.81 DYRK1A (0.60) DYRK1AFFAR1TGFBR1BMPR1ASMAD2
SCHEMBL22130152 0.81 DYRK1A (0.70) DYRK1AFFAR1TGFBR1BMPR1ASMAD2
SCHEMBL27558183 0.81 DYRK1A (0.60) DYRK1AFFAR1TGFBR1BMPR1ASMAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2018-04-05 US disclosed
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2018-04-05 US disclosed
US-9750740-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors Kanos Pharmaceuticals, Inc. (US) 2017-09-05 US disclosed
US-9750740-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors Kanos Pharmaceuticals, Inc. (US) 2017-09-05 US disclosed
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2017-04-06 US disclosed
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2017-04-06 US disclosed
US-9512122-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors KAROS PHARMACEUTICALS, INC. (US) 2016-12-06 US disclosed
US-20160096836-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2016-04-07 US disclosed
US-9199994-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors KAROS PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-20150080393-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2015-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080393-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A DYRK1A 1189/4885FFAR1 719/4885TGFBR1 1208/4885
US-20180092918-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A DYRK1A 1189/4885FFAR1 719/4885TGFBR1 1208/4885
US-20170095476-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A DYRK1A 1189/4885FFAR1 719/4885TGFBR1 1208/4885
US-20160096836-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A DYRK1A 1189/4885FFAR1 719/4885TGFBR1 1208/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A DYRK1A 1189/4885FFAR1 719/4885TGFBR1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.